Epidemiology of Henoch-Schönlein purpura

FRANK T. SAULSBURY, MD

Epidemiology is the study of diseases and the factors associated with the occurrence of diseases in defined populations. The epidemiology of most diseases can be viewed on two levels. Traditional macro-epidemiology examines the influence of age, gender, ethnic background, geography, environmental factors, and other variables on the susceptibility to a given disease. Micro-epidemiology examines the genetic and molecular factors that render some individuals or populations susceptible to a disease and others protected. This paper will review the macro-epidemiology of Henoch-Schönlein purpura (HSP) and discuss recent advances in understanding the micro-epidemiology of HSP.

MACRO-EPIDEMIOLOGY

HSP is an acute vasculitis that primarily affects children. The dominant clinical manifestations include purpura, arthritis, abdominal pain, gastrointestinal bleeding, and nephritis. The clinical features of HSP are a consequence of widespread leukocytoclastic vasculitis owing to IgA deposition in vessel walls. IgA deposition in the renal mesangium causes nephritis in some patients.

HSP is the most common acute vasculitis affecting children, with an incidence of approximately 10 cases per 100,000 children per year. Most studies on the incidence of HSP have been performed in Europe and the Middle East. There is little available information comparing the incidence of HSP in other parts of the world or in populations of widely disparate ethnic origins. HSP has been reported in patients as young as 6 months of age to as old as 86 years, but the vast majority of patients with HSP are young children. The mean age of the patients in most large series is 6 years. Approximately 75% of children are less than 8 years of age, and 90% are less than 10 years of age. Most studies report slightly more boys affected (60%) than girls (40%).

HSP occurs throughout the year, but a number of studies have noted seasonal skewing, with most patients presenting from fall through spring, and a paucity of cases during the summer months. Clusters or epidemics of HSP are rare. Farley et al reported a cluster of 16 cases of HSP, including 2 pairs of siblings during a 7-month period in Connecticut. However, other large epidemiologic studies have found no evidence of geographic or temporal clustering of cases. Moreover, the occurrence of multiple cases within a family is very uncommon.

Schönlein was the first to observe that respiratory infections commonly precede the onset of symptoms, an observation that has subsequently been made by many authors. Given the epidemiology of HSP (a disease affecting young children with a peak occurrence during the fall and winter months), it is not surprising that a large proportion of children have a history of upper respiratory infection. Nevertheless, there have been very few controlled studies examining the incidence of infections with specific pathogens in children with HSP compared to control children.

Of all the pathogens linked to HSP, group A beta-hemolytic streptococcus (GABS) has been the most extensively studied. Gairdner first proposed that HSP was associated with GABS infection in 1948. In Gairdner’s study, 50% of patients but only 10% of controls had a positive throat culture for GABS. Subsequent studies, many without controls, found positive throat cultures for GABS in 10-30% of patients and increased antistreptolysin O (ASO) titers in 20-50% of patients. Al-Sheyyab et al reported a statistically significantly higher proportion of children with HSP had increased ASO titers compared to controls. Other studies, however, have found no increased incidence of concomitant or preceding GABS infection in children with HSP compared to control children.

Taken together, these results indicate that a substantial minority of children with HSP have concurrent or recent GABS infection, but most cases have no direct link to GABS infection.

Anecdotal reports have implicated virtually every microbial pathogen in the etiology of HSP. However, very few studies have compared the incidence of infection with a specific pathogen in HSP versus controls. For example, there are a number of reports of parvovirus B19 infection in patients with HSP, but a recent study demonstrated the incidence of acute parvovirus B19 infection was no different in children with HSP compared to control children. In addition to infections, HSP has been associated with a wide variety of drugs and other agents. Nevertheless, none of these agents have been proved to be associated with HSP in controlled studies. Thus, despite extensive efforts and scores of anecdotal reports, there appears to be no single pathogen or environmental agent that has emerged as a dominant precipitating cause of HSP.

From the Division of Immunology and Rheumatology, Department of Pediatrics, University of Virginia Health System, Charlottesville. Address correspondence to FTS, Department of Pediatrics, Box 80386, University of Virginia Health System, Charlottesville, VA 22908. E-mail: fts@virginia.edu
There are important differences in the epidemiology and the clinical features of HSP in adults compared to children. The incidence of HSP in adults is about one-tenth that of children, with available data indicating 13-14 cases per 1,000,000 adults per year.\textsuperscript{13,14} In several large series, the mean age of adults with HSP was approximately 50 years. Men and women are affected with equal frequency. There is little seasonal variability, and preceding infections are less common in adults compared to children. HSP is often more severe in adults. Nephritis occurs in 50-80% of adults, but only 20-40% of children. Ten to twenty percent of adults with HSP nephritis develop end-stage renal disease compared to 1% of children.\textsuperscript{15,16}

\section*{MICRO-EPIEpidemiology}

Although the etiology is unknown, it is clear that IgA plays a pivotal role in the pathogenesis of HSP. HSP is associated with a variety of abnormalities involving IgA, including increased serum IgA concentrations, IgA-containing circulating immune complexes, and IgA deposition in vessel walls and renal mesangium. There are two subclasses of IgA—IgA1 and IgA2. IgA1 accounts for 80-90% of serum IgA, while secretory IgA is composed of roughly equal proportions of IgA1 and IgA2. It is noteworthy that HSP is associated with abnormalities involving only IgA1, but not IgA2. The reasons for the exclusive involvement of IgA1 in the immunopathogenesis of HSP are beginning to emerge.

One important difference between IgA1 and IgA2 involves the hinge region of the heavy chain, and the glycosylation sites therein. IgA1 contains a proline-rich hinge region between the CH1 and CH2 domains of the heavy chain. It is composed of 18 amino acids, of which 5 are O-linked glycosylation sites. The basic structure is N-acetylgalactosamine (GalNAc) O-linked to serine or threonine. The oligosaccharide chain is usually extended by the addition of galactose (Gal) in β1,3 linkage with GalNAc, and with one or two sialic acid residues in α2,3 linkage with Gal or α2,6 linkage with GalNAc. IgA2 molecules do not contain a heavy-chain hinge region and, thus, no O-linked oligosaccharides.

\section*{REFERENCES}

16. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M, Gonzalez-Gay MA. Henoch-Schönlein purpura in...
HENOCH-SCHÖNLEIN PURPURA